Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May 1;106(5):e262-e263.
doi: 10.1097/TP.0000000000004092. Epub 2022 Feb 15.

Improved Antibody Response After a Fifth Dose of a SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series

Aura T Abedon  1 , Mayan S Teles  1 , Jennifer L Alejo  1 , Jake D Kim  1 , Jonathan Mitchell  1 , Teresa P Y Chiang  1 , Robin K Avery  2 , Aaron A R Tobian  3 , Macey L Levan  1   4 , Daniel S Warren  1 , Allan B Massie  1   5 , Jacqueline M Garonzik-Wang  6 , Dorry L Segev  1   5 , William A Werbel  2
Affiliations

Improved Antibody Response After a Fifth Dose of a SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series

Aura T Abedon et al. Transplantation. .

Abstract

formula image

PubMed Disclaimer

Conflict of interest statement

D.L.S. received consulting and speaking honoraria from Sanofi, Novartis, CLS Behring, Jazz Pharmaceuticals, Veloxis, Mallinckrodt, Thermo Fisher Scientific, Regeneron, and AstraZeneca. M.L.L. is the Social Media Editor for Transplantation. R.K.A. has grant/research support from Aicuris, Astellas, Chimerix, Merck, Oxford Immunotec, Qiagen, and Takeda/Shire. The other authors declare no conflicts of interest.

Figures

FIGURE 1.
FIGURE 1.
Antibody responses after SARS-CoV-2 vaccination among solid organ transplant recipients. RBD, receptor-binding domain; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
See this image and copyright information in PMC

Comment in

References

    1. Callaghan CJ, Mumford L, Curtis RMK, et al. . Real-world effectiveness of the Pfizer-BioNTech BNT162b2 and Oxford-AstraZeneca ChAdOx1-S vaccines against SARS-CoV-2 in solid organ and islet transplant recipients. Transplantation. [Epub ahead of print. January 4, 2022]. doi:10.1097/TP.0000000000004059 - PMC - PubMed
    1. Chapman JR, Wigmore SJ. Simple vaccination is not enough for the transplant recipient. Transplantation. [Epub ahead of print. January 4, 2022]. doi:10.1097/TP.0000000000004064 - PMC - PubMed
    1. Karaba AH, Zhu X, Liang T, et al. . A third dose of SARS-CoV-2 vaccine increases neutralizing antibodies against variants of concern in solid organ transplant recipients. Am J Transplant. 2022;00:7. - PMC - PubMed
    1. Reindl-Schwaighofer R, Heinzel A, Mayrdorfer M, et al. . Comparison of SARS-CoV-2 antibody response 4 weeks after homologous vs heterologous third vaccine dose in kidney transplant recipients. JAMA Intern Med. 2021;182:e217372. - PMC - PubMed
    1. Alejo JL, Mitchell J, Chiang TP-Y, et al. . Antibody response to a fourth dose of a SARS-CoV-2 vaccine in solid organ transplant recipients: a case series. Transplantation. 2021;105:e280–e281. - PMC - PubMed

Publication types